TD Cowen raised the firm’s price target on Tandem Diabetes to $45 from $35 and keeps a Buy rating on the shares. The firm said they remain constructive on the company given its compelling new product roster which includes Mobi the world s smallest durable AID system.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Wells upgrades Tandem Diabetes on positive endocrinologist survey
- Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
- Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
- Tandem Diabetes upgraded to Outperform from Market Perform at Leerink
- Tandem Diabetes price target raised to $40 from $37 at Stifel